Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%
26 oct. 2017 07h00 HE
|
ABIOMED, Inc.
DANVERS, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2018 revenue of...
Abiomed's Impella® Technology that Enables Heart Recovery Showcased at TCT 2017 With More Than 30 Presentations
19 oct. 2017 16h00 HE
|
ABIOMED, Inc.
DANVERS, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 30...
Abiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification
10 oct. 2017 08h00 HE
|
Abiomed
DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, October 26, 2017, the Company will release financial results for the second quarter of...
Abiomed recebe aprovação PMA da FDA para a bomba cardíaca Impella RP® para insuficiência cardíaca direita
22 sept. 2017 17h28 HE
|
Abiomed
DANVERS, Massachusetts, Sept. 22, 2017 (GLOBE NEWSWIRE) -- A Abiomed, Inc. (NASDAQ:ABMD), provedora líder de tecnologias revolucionárias de suporte e recuperação cardíacos, anunciou hoje que recebeu...
Abiomed Menerima Kelulusan FDA PMA untuk Impella RP® untuk Kegagalan Jantung Kanan
22 sept. 2017 17h28 HE
|
Abiomed
DANVERS, Mass., Sept. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), penyedia peneraju untuk teknologi sokongan dan pemulihan jantung, hari ini mengumumkan bahawa ia telah menerima...
Abiomed ได้รับการรับรองผลิตภัณฑ์ก่อนออกสู่ตลาด (PMA) จาก FDA สำหรับ Impella RP® เพื่อใช้รักษาหัวใจห้องล่างขวาล้มเหลว
22 sept. 2017 17h28 HE
|
Abiomed
แดนเวอร์ รัฐแมสซาชูเซตส์, Sept. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) ผู้นำเทคโนโลยีการช่วยเหลือหัวใจเลือดเล็ดลอดและการฟื้นสภาพหัวใจ...
Abiomed Menerima Persetujuan FDA PMA bagi Impella RP® untuk Gagal Jantung Kanan
22 sept. 2017 17h28 HE
|
Abiomed
DANVERS, Mass., Sept. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), penyedia terobosan dukungan dan teknologi pemulihan jantung terkemuka, hari ini mengumumkan telah menerima persetujuan...
Abiomed 的 Impella RP® 獲得美國食品藥物管理局 (FDA) 上市前核准 (PMA) 可用於治療右心衰竭
22 sept. 2017 17h28 HE
|
Abiomed
馬薩諸塞州丹佛斯市, Sept. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc.(NASDAQ:ABMD)，一間領先的突破性心臟支援及功能恢復技術供應商，今日發佈消息稱，公司的 Impella RP® 心臟泵獲得美國食品藥物管理局 (FDA) 上市前核准 (PMA)。歷經五年的研究工作告一段落，此項批准緊隨先前於 2015 年 1 月所獲得的 FDA...
아비오메드의 우심부전용 Impella RP®, FDA로부터 시판 전 허가(PMA) 획득
22 sept. 2017 17h28 HE
|
Abiomed
미국 매사추세츠주 댄버스, Sept. 23, 2017 (GLOBE NEWSWIRE) -- 혁신적인 심장 보조장치 기술을 개발하는 선도기업 아비오메드(Abiomed, Inc.)(NASDAQ:ABMD)는 미국 식품의약국(FDA)으로부터 Impella RP® 인공심장 펌프에 대한 시판 전 허가(PMA)를 획득했다고 밝혔다. 지난 5년 동안 연구를 통해 개발한...
Abiomed获得FDA PMA批准其Impella RP®用于治疗右心衰竭
22 sept. 2017 17h28 HE
|
Abiomed
马萨诸塞州丹弗斯, Sept. 23, 2017 (GLOBE NEWSWIRE) -- 突破性心脏支持和恢复技术的领先提供商Abiomed,Inc. (NASDAQ: ABMD) 今天宣布已收到美国食品和药物管理局（FDA）对于Impella...